2026 年至 2032 年人工心臟市场类型、技术、最终用户和地区分布

2026-2032年人工心臟市场估值

人工心臟的需求正在迅速增长，这主要是由于全球心血管疾病的发生率不断上升。心臟衰竭通常由冠状动脉疾病、高血压和心臟病发作等疾病引起，并且随着世界人口老化和生活方式相关健康问题的增加而变得越来越普遍。遗憾的是，用于移植的捐赠心臟供应有限，导致需要器官的人数与可用器官数量之间存在巨大差距。因此，预计该市场销售额将在2024年超过25.9亿美元，并在2032年达到约73.4亿美元的估值。

技术突破也大大促进了人工心臟需求的成长。材料科学、微型化和生物相容性的进步，为更精密、更能模拟自然心臟活动的人工心臟铺平了道路。这些技术创新透过最大限度地减少问题并延长设备使用寿命，改善了患者的生活质量，使市场在2026年至2032年间的复合年增长率达到13.92%。

人工心臟市场定义/概述

人工心臟是一种机械装置，可以暂时或永久地取代衰竭的人类心臟，维持身体的血液流动和氧气供应。人工心臟主要用于患有严重心臟病（例如末期心臟衰竭）的患者，这些患者的心臟无法再有效地泵血。人工心臟透过循环系统泵血，复製自然心臟的功能，确保重要器官获得正常运作所需的氧气和营养。

人工心臟是一种革命性的医疗设备，它可以取代衰竭的人类心臟功能，为患有严重心臟疾病的患者提供挽救生命的支持。人工心臟的一个重要应用是作为心臟移植的过渡。当末期心臟衰竭患者的心臟无法正常泵血时，人工心臟可以暂时取代衰竭的器官。这使得患者在等待移植心臟的过程中能够存活下来。

未来机械心臟的应用可望彻底改变循环系统，为严重心臟疾病患者带来新的希望。随着全球心臟病负担的不断加重，对于那些因医疗原因（例如缺乏捐赠器官）无法接受心臟移植的患者来说，人工心臟正成为一个越来越重要的选择。这些人工心臟的设计工作原理与自然心臟相似，能够将血液泵送到全身，延长心臟功能。

它的目的是将血液泵送到全身，即使病人自己的心臟停止运作，也能延长生命。

心血管疾病发生率的上升会推动人工心臟市场的发展吗？

心血管疾病 (CVD) 发生率的上升是人工心臟市场的主要驱动力。根据世界卫生组织 (WHO) 的数据，心血管疾病是全球首要的死亡原因，每年约导致 1,790 万人死亡。这占全球整体的 31%。心血管疾病的盛行率持续上升，尤其是在中低收入国家，这些国家占心血管疾病死亡人数的 75% 以上。根据美国疾病管制与预防中心 (CDC) 的数据，光是在美国，心臟病就是首要的死亡原因，每年约导致 655,000 人死亡（四分之一的死亡人数）。

心血管疾病 (CVD) 盛行率的惊人上升预计将增加对人工心臟的需求，因为人工心臟是终末期心臟衰竭患者的救命治疗方法。根据美国心肺血液研究所 (NHLBI) 的估计，美国约有 620 万成年人心臟衰竭，预计到 2030 年将增加至 800 多万人。此外，器官共享美国网络 (UNOS) 报告称，截至 2021 年，美国有超过 3,500 人在等待心臟移植。由于捐赠心臟持续短缺，人工心臟成为移植的重要过渡选择，或在某些情况下作为最终治疗手段。

高成本会阻碍人工心臟市场的发展吗？

人工心臟的高成本是其市场拓展的主要障碍，并可能限制其广泛采用和普及。据美国国立卫生研究院 (NIH) 称，人工心臟植入物的总成本（包括装置和相关医疗费用）在 15 万至 50 万美元之间。许多患者和医疗保健系统，尤其是在开发中国家和地区，辅助人工心臟(VAD)，但完整的人工心臟植入物通常不在保险范围内，这进一步限制了经常需要此类手术的老年患者获得此类服务。

高成本对该领域的研发以及病患的用药管道都产生了影响。食品药物管理局(FDA) 声称，人工心臟核准所需的漫长临床试验耗资数亿美元，阻碍了一些公司进入市场或开发创新设计。如此高的进入门槛可能会抑制技术发展、阻碍竞争，并导致长期高成本。此外，美国国家心肺血液研究所 (NHLBI) 表示，儘管近年来政府对人工心臟研究的资助有所增加，但仍不足以刺激该领域的快速创新和成本降低。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章 人工心臟市场（依类型）

• 全人工心臟（TAH）
• 左心室补助人工心臟（LVAD）

第五章 人工心臟市场（依技术）

• 常用技术
• 脉动流技术

第六章 人工心臟市场（依最终用户）

• 医院
• 门诊手术中心（ASC）

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• SynCardia Systems, LLC
• Carmat
• Abiomed
• CryoLife, Inc.
• ReinHeart TAH GmbH
• Jarvik Heart, Inc.
• Calon Cardio-Technology Ltd.
• BiVACOR, Inc.
• CARMAT SA
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Artificial Heart Market Valuation - 2026-2032

The demand for artificial hearts is quickly expanding owing mostly to the rising global frequency of cardiovascular disorders. Heart failure which is frequently caused by illnesses such as coronary artery disease, high blood pressure, and heart attacks is growing increasingly widespread as the world's population ages and lifestyle-related health issues increase. Unfortunately, the supply of donor hearts for transplantation is limited resulting in a considerable disparity between the number of people in need and the organs available by enabling the market to surpass a revenue of USD 2.59 Billion valued in 2024 and reach a valuation of around USD 7.34 Billion by 2032.

Technological breakthroughs are also contributing significantly to the growing demand for artificial hearts. Materials science, downsizing, and biocompatibility advancements are paving the way for more sophisticated artificial hearts that can better replicate natural cardiac activities. These innovations improve patient's quality of life by minimizing problems and increasing the device's lifespan by enabling the market to grow at a CAGR of 13.92% from 2026 to 2032.

Artificial Heart Market: Definition/ Overview

An artificial heart is a mechanical device that replaces a failing human heart, either temporarily or permanently, to keep blood flowing and oxygen delivered to the body. It is primarily used in individuals with severe heart diseases including as end-stage heart failure in which the heart is no longer able to efficiently pump blood. The artificial heart replicates the natural heart's function by pumping blood through the circulatory system ensuring that essential organs receive the oxygen and nutrition they require to function.

The artificial heart is a groundbreaking medical device that replaces the function of a failing human heart providing life-saving support to patients suffering from serious cardiac diseases. One of the key uses for artificial hearts is as a bridge to heart transplantation. An artificial heart can temporarily replace the failing organ in individuals with end-stage heart failure in which the heart can no longer adequately pump blood. This enables patients to survive while awaiting a donor heart for transplantation.

The future usage of mechanical hearts has the potential to change cardiology providing new hope to patients with serious cardiac diseases. As the global burden of heart disease rises, artificial hearts are becoming an increasingly important option for patients who are unable to receive heart transplants due to a lack of donor organs or other medical reasons. These devices are designed to perform similarly to a natural heart moving

blood throughout the body and prolonging life when the patient's own heart is no longer functioning.

Will the Rising Incidence of Cardiovascular Diseases Drive the Artificial Heart Market?

The increasing incidence of cardiovascular diseases (CVDs) is a major driver of the artificial heart market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. This accounts for 31% of all deaths globally. CVD prevalence has continuously increased, particularly in low- and middle-income nations which account for more than 75% of CVD deaths. In the United States alone, the Centers for Disease Control and Prevention (CDC) says that heart disease is the leading cause of death accounting for around 655,000 fatalities yearly or one in every four deaths.

This worrying rise in CVD prevalence is predicted to increase demand for artificial hearts as a life-saving treatment for individuals with end-stage heart failure. The National Heart, Lung, and Blood Institute (NHLBI) estimates that roughly 6.2 million adults in the United States have heart failure with projections indicating that this figure could rise to over 8 million by 2030. Furthermore, the United Network for Organ Sharing (UNOS) reports that as of 2021, there were over 3,500 people on the waiting list for a heart transplant in the United States. Given the ongoing paucity of donor hearts, artificial hearts serve as an important bridge-to-transplant option or, in certain situations, a destination therapy.

Will the High-Cost Hamper the Artificial Heart Market?

The high cost of artificial hearts poses a substantial barrier to market expansion, potentially limiting adoption and accessibility. According to the National Institute of Health (NIH), the overall cost of an artificial heart transplant including the device and related medical care can range between $150,000 and $500,000. Many patients and healthcare systems, particularly in developing countries or locations with low healthcare resources are unable to afford mechanical hearts due to the significant financial load. According to the Centers for Medicare and Medicaid Services (CMS), while they cover certain ventricular assist devices (VADs) for qualifying beneficiaries, full artificial heart transplants are not usually reimbursed, further limiting access for elderly patients who frequently require such operations.

The high cost has an impact not just on patient access but also on research and development in the sector. The Food and Drug Administration (FDA) has claimed that the long clinical trials required for artificial heart approval can cost manufacturers hundreds of millions of dollars discouraging some companies from joining the market or developing novel designs. This expensive barrier to entry may stifle technological developments and hinder competition, thus maintaining high costs in the long run. Furthermore, the National Heart, Lung, and Blood Institute (NHLBI) has stated that, while government funding for artificial heart research has increased in recent years, it remains insufficient to encourage rapid innovation and cost reduction in the sector.

Category-Wise Acumens

Will Broader Application and Widespread Adoption Drive Growth in the Type Segment?

Left Ventricular Assist Devices (LVADs) are in a dominant position owing to their broad application and widespread adoption in treating patients with severe heart failure. LVADs are intended to support the left ventricle, the heart's major pumping chamber responsible for delivering oxygen-rich blood to the body. These devices are frequently utilized as a bridge to heart transplantation providing critical-care patients with the essential assistance while they wait for a donor heart. Furthermore, LVADs are increasingly being used as destination therapy for patients who are not candidates for transplantation due to age, comorbidities, or other criteria.

The incidence of heart failure, particularly among the elderly has contributed to the demand for LVADs. As the world's population ages, the prevalence of heart failure is predicted to climb creating a higher demand for advanced treatments such as LVADs. Furthermore, technological advances in LVAD design have resulted in smaller, more efficient, and easier-to-implant devices lowering surgical risks while increasing patient outcomes. Wireless power transfer and better biocompatible materials have improved the safety and endurance of LVADs making them more appealing to patients and healthcare professionals.

Will the Ongoing Research and Development Drive the Technology Segment?

Continuous flow technology has emerged as the dominant force, owing to major improvements over prior pulsatile flow systems. Continuous flow artificial hearts use a continuous, non-pulsatile mechanism to pump blood throughout the body providing several significant benefits that make them the favored choice in the medical profession. One of the key advantages is their tiny size which enables easier implantation in a broader range of patients including those with lower body proportions. This downsizing has made the technology more accessible and minimally intrusive resulting in better patient outcomes and shorter recovery periods.

Furthermore, continuous flow devices are noted for their long lifespan. Because they work on a consistent, continuous basis without the need for moving elements to contract and expand like normal heartbeats, Continuous flow technology not only leads the artificial heart market but it also symbolizes the future of cardiac support systems. Continuous research and development in this area improves the performance and reliability of these devices, further distinguishing them from their pulsatile predecessors. The medical community's choice of continuous flow devices is also influenced by the larger trend toward minimally invasive and long-lasting cardiac care solutions. This trend is likely to continue as technology advances ensuring that continuous flow artificial hearts stay at the forefront of life-saving cardiac procedures.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in the North American Region?

The North American region, particularly the United States and Canada is well-positioned to dominate the artificial heart industry due to its advanced healthcare infrastructure and significant investments in medical technology. North America, notably the United States, has some of the world's most complex healthcare systems with cutting-edge medical facilities, robust research and development skills, and significant investment in healthcare technology. These variables work together to produce an atmosphere that encourages the acceptance and development of advanced medical equipment such as artificial hearts.

The North American market benefits from an established regulatory structure that facilitates the approval and marketing of breakthrough medical innovations. The US Food and Drug Administration (FDA) is an important player in this process ensuring that new medical devices fulfill high safety and efficacy requirements before they are released to the market. This stringent approval process, though difficult, ultimately contributes to the trust and confidence that healthcare providers and patients have in these devices. The availability of significant funding and payment options for sophisticated cardiac treatments makes artificial hearts more accessible to patients, which drives market growth. Furthermore, the region's aging population, which is increasingly susceptible to heart-related ailments raises the need for effective cardiac support systems.

Will the Demand for Advanced Cardiac Therapies Drive the Market in the Asia Pacific Region?

The Asia Pacific region is expected to be the fastest-growing artificial heart market owing to increased cardiovascular disease prevalence and healthcare expenditure. This rapid expansion is primarily attributable to the vast population base, improved healthcare infrastructure, and increased awareness of innovative cardiac therapy in nations such as China, Japan, and India.

The demand for innovative cardiac therapy in Asia Pacific is projected to drive the artificial heart industry. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortality worldwide claiming an estimated 17.9 million lives per year. In the Western Pacific region which includes many Asian countries, cardiovascular diseases account for 35% of all deaths.

The increased frequency of CVD combined with an aging population is driving significant demand for sophisticated cardiac treatments including artificial hearts. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Asia and the Pacific's elder population is predicted to grow from 630 million in 2020 to approximately 1.3 billion by 2050. This demographic transition is projected to increase the incidence of heart failure, and thus the demand for artificial hearts. Furthermore, increased healthcare spending in the region is encouraging the use of modern medical technologies.

Competitive Landscape

The Artificial Heart Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the artificial heart market include:

• Jarvik Heart, Inc.
• BiVACOR, Inc.
• CARMAT SA
• SynCardia Systems, LLC
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

Latest Developments

• In September 2023, Abbott (NYSE: ABT) announced the completion of its acquisition of Bigfoot Biomedical, a market leader in the creation of smart insulin control devices for diabetics.

Artificial Heart Market, By Category

• Type:
• Total Artificial Hearts (TAH)
• Left Ventricular Assist Devices (LVAD)
• Technology:
• Continuous Flow Technology
• Pulsatile Flow Technology
• End-User:
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. INTRODUCTION

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Artificial Heart Market, By Type

• Total Artificial Hearts (TAH)
• Left Ventricular Assist Devices (LVAD)

5. Artificial Heart Market, By Technology

• Continuous Flow Technology
• Pulsatile Flow Technology

6. Artificial Heart Market, By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• SynCardia Systems, LLC
• Carmat
• Abiomed
• CryoLife, Inc.
• ReinHeart TAH GmbH
• Jarvik Heart, Inc.
• Calon Cardio-Technology Ltd.
• BiVACOR, Inc.
• CARMAT SA
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References